MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/iid3.70270

Медицинская библиотека · Immunity, inflammation and disease · 2025

Risk Factors of Progression to Active Tuberculosis in Rheumatic Patients With Latent Tuberculosis: A Retrospective Study.

Wang Fengjuan, Zhou Lei, Hao Xiaoyan, Liu Jiayun

СтатьяПеревод в очереди

Аннотация

BACKGROUND

In rheumatism patients, the immune system erroneously attacks the body's own tissues. This impairs the body's defense against external pathogens and is a contributing factor to the occurrence of tuberculosis infection. The primary objective of this investigation was to examine the risk factors for the progression from latent tuberculosis infection (LTBI) to active tuberculosis (ATB) in patients with rheumatic diseases (RD).

METHODS

RD cover a wide range of disorders affecting the skeletal system, joints, and adjacent soft tissues. When the human body is infected by Mycobacterium tuberculosis, the condition is classified as either LTBI or ATB, depending on the presence or absence of typical clinical symptoms. A retrospective study was conducted at the Xijing Hospital of the Fourth Military Medical University. Specifically, the Laboratory Information System was used to investigate patients diagnosed with RD from January 2012 to October 2022.

RESULTS

The study included a total of 32,235 individuals diagnosed with rheumatism, of whom only 18.60% were screened for LTBI. The overall incidence of LTBI was 25.33%. Among the 629 RD inpatients with LTBI, systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) accounted for half, and 56.44% received glucocorticoid (GC) therapy. Risk-factor assessment for ATB was conducted in 247 cases. A GC dose of 20 mg/day or more was an independent risk factor for LTBI activation (odds ratio = 3.59, 95% CI: 1.26-10.29, p = 0.017).

CONCLUSION

In China, RD patients have a relatively high risk of LTBI. In clinical practice, LTBI screening should be routinely performed for RD patients before initiating GC therapy at a dose of ≥ 20 mg/day. For patients with SLE and RA undergoing continuous GC treatment, close monitoring is essential. In addition, clinicians should enhance the diagnostic pathways and treatment management for these patients to prevent the occurrence of ATB.

Для цитирования: Wang Fengjuan, Zhou Lei, Hao Xiaoyan, Liu Jiayun. Risk Factors of Progression to Active Tuberculosis in Rheumatic Patients With Latent Tuberculosis: A Retrospective Study.. Immunity, inflammation and disease. 2025. DOI: 10.1002/iid3.70270.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.